{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:56:14Z","timestamp":1793084174152,"version":"4.5.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","award":["R01 AR077103"],"award-info":[{"award-number":["R01 AR077103"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ingegerd Johansson Donation","award":["SLS-714651"],"award-info":[{"award-number":["SLS-714651"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the infant risk of major congenital malformations (MCM) associated with first-trimester exposure to hydroxychloroquine (HCQ) among mothers with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This population-based cohort study utilized Swedish nationwide registers and included all singleton births (2006\u20132021) among individuals with prevalent SLE or RA in Sweden. The exposure was filling \u22651 HCQ prescription during the first trimester. The outcome was infant MCM within 1\u2009year of birth. Inverse probability of treatment weighting was applied to adjust for potential confounders (e.g. maternal smoking, body mass index, pregestational diabetes and corticosteroids). Modified Poisson regression models with robust variance were used to estimate risk ratios (RR) and 95% CI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 1007 births (453 exposed) and 2500 births (144 exposed) in the SLE and RA cohorts, respectively. The MCM risks in the SLE overall cohort, exposed and unexposed groups were 3.6%, 3.7% and 3.4%, respectively. The corresponding figures in the RA cohort were 4.4%, 5.6% and 4.3%, respectively. The adjusted RRs (95% CI) were 1.29 (0.65, 2.56) in the SLE cohort, 1.32 (0.56, 3.13) in the RA cohort and 1.30 (0.76, 2.23) in the pooled analysis. The adjusted risk difference (exposed vs unexposed) was small (0.9% in SLE and 1.3% in RA). Sensitivity analyses examining different exposure and outcome windows yielded similar findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>First-trimester exposure to HCQ was not associated with a significantly increased risk of MCM. HCQ\u2019s benefits may outweigh the risks in managing SLE or RA during pregnancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae168","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T11:30:48Z","timestamp":1710243048000},"page":"117-125","source":"Crossref","is-referenced-by-count":25,"title":["Hydroxychloroquine in lupus or rheumatoid arthritis pregnancy and risk of major congenital malformations: a population-based cohort study"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4455-3171","authenticated-orcid":false,"given":"Ngoc V","family":"Nguyen","sequence":"first","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3396-3244","authenticated-orcid":false,"given":"Elisabet","family":"Svenungsson","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annica","family":"Dominicus","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Altman","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7149-0973","authenticated-orcid":false,"given":"Karin","family":"Hellgren","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5735-9856","authenticated-orcid":false,"given":"Julia F","family":"Simard","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet , Stockholm,","place":["Sweden"]},{"name":"Division of Immunology and Rheumatology, Department of Medicine, Stanford School of Medicine , Stanford, CA,","place":["USA"]},{"name":"Department of Epidemiology and Population Health, Stanford School of Medicine , Stanford, CA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth V","family":"Arkema","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"key":"2025010608390624300_keae168-B1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s43032-022-00901-6","article-title":"Rheumatic diseases in reproductive age-the possibilities and the risks","volume":"30","author":"Grygiel-G\u00f3rniak","year":"2023","journal-title":"Reprod Sci Thousand Oaks Calif"},{"key":"2025010608390624300_keae168-B2","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women\u2019s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025010608390624300_keae168-B3","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"G\u00f6testam Skorpen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025010608390624300_keae168-B4","doi-asserted-by":"crossref","first-page":"e48\u201388","DOI":"10.1093\/rheumatology\/keac558","article-title":"British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids","volume":"62","author":"Russell","year":"2023","journal-title":"Rheumatology"},{"key":"2025010608390624300_keae168-B5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.41191","article-title":"2020 American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025010608390624300_keae168-B6","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1002\/art.22159","article-title":"Hydroxychloroquine in lupus pregnancy","volume":"54","author":"Clowse","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2025010608390624300_keae168-B7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/0961203314555352","article-title":"Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus","volume":"24","author":"Koh","year":"2015","journal-title":"Lupus"},{"key":"2025010608390624300_keae168-B8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1191\/096120301678646137","article-title":"Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study","volume":"10","author":"Levy","year":"2001","journal-title":"Lupus"},{"key":"2025010608390624300_keae168-B9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1546-0096-7-9","article-title":"Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases","volume":"7","author":"Sperber","year":"2009","journal-title":"Pediatr Rheumatol Online J"},{"key":"2025010608390624300_keae168-B10","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1093\/rheumatology\/keaa592","article-title":"Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study","volume":"60","author":"Andersson","year":"2021","journal-title":"Rheumatol Oxf Engl"},{"key":"2025010608390624300_keae168-B11","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/art.10150","article-title":"Evidence of transplacental passage of hydroxychloroquine in humans","volume":"46","author":"Costedoat-Chalumeau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2025010608390624300_keae168-B12","first-page":"122","article-title":"Effects of hydroxychloroquine on the growth of mammalian cells in vitro","volume":"141","author":"Gabourel","year":"1963","journal-title":"J Pharmacol Exp Ther"},{"key":"2025010608390624300_keae168-B13","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/art.38262","article-title":"Brief report: risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy","volume":"66","author":"Cooper","year":"2014","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"2025010608390624300_keae168-B14","doi-asserted-by":"crossref","first-page":"722511","DOI":"10.3389\/fphar.2021.722511","article-title":"Chloroquine and hydroxychloroquine use during pregnancy and the risk of adverse pregnancy outcomes using real-world evidence","volume":"12","author":"B\u00e9rard","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025010608390624300_keae168-B15","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/bdr2.1943","article-title":"Maternal exposure to hydroxychloroquine and birth defects","volume":"113","author":"Howley","year":"2021","journal-title":"Birth Defects Res"},{"key":"2025010608390624300_keae168-B16","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/rheumatology\/keac372","article-title":"Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine","volume":"62","author":"Reynolds","year":"2023","journal-title":"Rheumatology"},{"key":"2025010608390624300_keae168-B17","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1002\/art.11304","article-title":"Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group","volume":"48","author":"Costedoat-Chalumeau","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2025010608390624300_keae168-B18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.reprotox.2013.04.005","article-title":"Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study","volume":"39","author":"Diav-Citrin","year":"2013","journal-title":"Reprod Toxicol Elmsford N"},{"key":"2025010608390624300_keae168-B19","doi-asserted-by":"crossref","first-page":"290.e1","DOI":"10.1016\/j.ajog.2020.09.007","article-title":"Hydroxychloroquine early in pregnancy and risk of birth defects","volume":"224","author":"Huybrechts","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"2025010608390624300_keae168-B20","author":"European Medical Agency","year":"2023"},{"key":"2025010608390624300_keae168-B21","author":"Heads of Medicines Agencies"},{"key":"2025010608390624300_keae168-B22","doi-asserted-by":"crossref","first-page":"e37\u20138","DOI":"10.1093\/rheumatology\/kead384","article-title":"British society of rheumatology guideline working group response to european medicines agency safety update on hydroxychloroquine","volume":"63","author":"Russell","year":"2024","journal-title":"Rheumatology"},{"key":"2025010608390624300_keae168-B23","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ajog.2020.12.1218","article-title":"Hydroxychloroquine early in pregnancy and risk of birth defects: don\u2019t throw out the baby with the bathwater","volume":"224","author":"Bermas","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"2025010608390624300_keae168-B24","doi-asserted-by":"crossref","first-page":"e501\u20136","DOI":"10.1016\/S2665-9913(23)00215-1","article-title":"Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases","volume":"5","author":"Schreiber","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2025010608390624300_keae168-B25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10654-022-00947-5","article-title":"The Swedish medical birth register during five decades: documentation of the content and quality of the register","volume":"8","author":"Cnattingius","year":"2023","journal-title":"Eur J Epidemiol"},{"key":"2025010608390624300_keae168-B26","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"2025010608390624300_keae168-B27","doi-asserted-by":"crossref","first-page":"e007769","DOI":"10.1136\/bmjopen-2015-007769","article-title":"Case definitions in Swedish register data to identify systemic lupus erythematosus","volume":"6","author":"Arkema","year":"2016","journal-title":"BMJ Open"},{"key":"2025010608390624300_keae168-B28","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/ard.2010.133371","article-title":"Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden","volume":"70","author":"Neovius","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2025010608390624300_keae168-B29","author":"Critical Periods of Development","year":"1994"},{"key":"2025010608390624300_keae168-B30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2025010608390624300_keae168-B31","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish Prescribed Drug Register\u2014opportunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025010608390624300_keae168-B32","author":"European Platform on Rare Disease Registration"},{"key":"2025010608390624300_keae168-B33","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10654-019-00511-8","article-title":"The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research","volume":"34","author":"Ludvigsson","year":"2019","journal-title":"Eur J Epidemiol"},{"key":"2025010608390624300_keae168-B34","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/aogs.13266","article-title":"The Swedish Pregnancy Register\u2014for quality of care improvement and research","volume":"97","author":"Stephansson","year":"2018","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2025010608390624300_keae168-B35","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/03009742.2011.626442","article-title":"Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers","volume":"41","author":"Viktil","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"2025010608390624300_keae168-B36","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.42015","article-title":"Birth Outcomes in Women Who Have Taken Hydroxycholoroquine During Pregnancy: a Prospective Cohort Study","volume":"74","author":"Chambers","year":"2022","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"2025010608390624300_keae168-B37","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/bcp.12872","article-title":"Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis","volume":"81","author":"Kaplan","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2025010608390624300_keae168-B38","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/0961203320985214","article-title":"The influence of obesity on hydroxychloroquine blood levels in lupus nephritis patients","volume":"30","author":"Pedrosa","year":"2021","journal-title":"Lupus"},{"key":"2025010608390624300_keae168-B39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025010608390624300_keae168-B40","doi-asserted-by":"crossref","first-page":"j2563","DOI":"10.1136\/bmj.j2563","article-title":"Risk of major congenital malformations in relation to maternal overweight and obesity severity: cohort study of 1.2 million singletons","volume":"357","author":"Persson","year":"2017","journal-title":"The BMJ"},{"key":"2025010608390624300_keae168-B41","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1001\/jama.2009.113","article-title":"Maternal overweight and obesity and the risk of congenital anomalies: a systematic review and meta-analysis","volume":"301","author":"Stothard","year":"2009","journal-title":"JAMA"},{"key":"2025010608390624300_keae168-B42"},{"key":"2025010608390624300_keae168-B43","first-page":"1","article-title":"Detection of major congenital malformations depends on length of follow-up in Swedish National Health Register Data: implications for pharmacoepidemiological research on medication safety in pregnancy","volume":"00","author":"Segovia Chac\u00f3n","year":"2023","journal-title":"Paediatr Perinat Epidemiol"},{"key":"2025010608390624300_keae168-B44","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/ppe.12650","article-title":"Quantification of selection bias in studies of risk factors for birth defects among livebirths","volume":"34","author":"Heinke","year":"2020","journal-title":"Paediatr Perinat Epidemiol"},{"key":"2025010608390624300_keae168-B45","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/CIRCULATIONAHA.111.089268","article-title":"Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA\/Ro-antibody-associated cardiac manifestations of neonatal lupus","volume":"126","author":"Izmirly","year":"2012","journal-title":"Circulation"},{"key":"2025010608390624300_keae168-B46","doi-asserted-by":"crossref","first-page":"e000651","DOI":"10.1136\/lupus-2021-000651","article-title":"Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data","volume":"9","author":"Clowse","year":"2022","journal-title":"Lupus Sci Med"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae168\/57468547\/keae168.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/1\/117\/57468547\/keae168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/1\/117\/57468547\/keae168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T03:40:09Z","timestamp":1736134809000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/1\/117\/7628323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,13]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,3,13]]},"published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae168","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,3,13]]}}}